Lupin, TB Alliance join hands for new therapy for drug-resistant tuberculosis

TB Alliance President and CEO Mel Spigelman said that partnering with Lupin -- a well-established manufacturer with experience delivering high-quality TB therapies -- will help further enable widespread access to the novel regimen while promoting a competitive market to drive affordability.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news